All In MedTech

FDA Clearance Tracker · P100034-S030

Optune

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jan 16, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jan 16, 2024

Approved

Time to decision

356 days

Received Jan 25, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P100034-S030
Device name
Optune
Applicant location
Baar
Received
Jan 25, 2023
Decided
Jan 16, 2024
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P100034

Device type

Device class
Class III

Every decision under product code NZK

FDA's approval statement

As written in FDA's record.

approval for the MAXPOINT BR-I (“MAXPOINT”) Optune transducer array layout software

Source documents

Other decisions for Novocure, GmbH

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.